Patents by Inventor Sam Gandy

Sam Gandy has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHOD AND COMPOSITION FOR GENERATING BASAL FOREBRAIN CHOLINERGIC NEURONS (BFCNs)
    Publication number: 20210130773
    Abstract: The invention relates to methods and compositions for developing basal forebrain cholinergic neurons (BFCNs) from stem cells, and in particular, BFCNs having repaired electrophysiological defects relating to one or more mutations in PSEN2, and to the use of such BFCNs in cell-based therapies to treat Alzheimer's disease.
    Type: Application
    Filed: January 11, 2021
    Publication date: May 6, 2021
    Inventors: Scott Noggle, Maitane Ortiz-Virumbrales, Sam Gandy, Ilya Kruglikov, Michelle Ehrlich
  • Method and composition for generating basal forebrain cholinergic neurons (BFCNS)
    Patent number: 10889800
    Abstract: The invention relates to methods and compositions for developing basal forebrain cholinergic neurons (BFCNs) from stem cells, and in particular, BFCNs having repaired electrophysiological defects relating to one or more mutations in PSEN2, and to the use of such BFCNs in cell-based therapies to treat Alzheimer's disease.
    Type: Grant
    Filed: May 25, 2018
    Date of Patent: January 12, 2021
    Assignees: New York Stem Cell Foundation, Inc., Icahn School of Medicine at Mount Sinai
    Inventors: Scott Noggle, Maitane Ortiz-Virumbrales, Sam Gandy, Ilya Kruglikov, Michelle Ehrlich
  • METHOD AND COMPOSITION FOR GENERATING BASAL FOREBRAIN CHOLINERGIC NEURONS (BFCNS)
    Publication number: 20190002826
    Abstract: The invention relates to methods and compositions for developing basal forebrain cholinergic neurons (BFCNs) from stem cells, and in particular, BFCNs having repaired electrophysiological defects relating to one or more mutations in PSEN2, and to the use of such BFCNs in cell-based therapies to treat Alzheimer's disease.
    Type: Application
    Filed: May 25, 2018
    Publication date: January 3, 2019
    Inventors: Scott Noggle, Maitane Ortiz-Virumbrales, Sam Gandy, Ilya Kruglikov, Michelle Ehrlich
  • Methods for identifying and using amyloid-inhibitory compounds
    Publication number: 20080085244
    Abstract: The present invention relates to identification of agents that pay a role in regulating brain amyloid-? (A?) levels in vivo. The invention provides compounds and methods of using such compounds to treat amyloidogenic conditions. It also provides a useful animal model for screening for and evaluating candidate amyloid inhibiting or therapeutic compounds. In particular, ovariectomy (ovx) and estrogen replacement were found to affect brain A?, levels in guinea pigs. Long-term ovx of guinea pigs resulted in increased levels of total brain A?, as compared to intact animals, and the A?42/A?40 ratio was also elevated. Treatment of ovx guinea pigs with ?17-estradiol for ten days partially reversed the ovx-associated increase in brain A? levels.
    Type: Application
    Filed: December 7, 2007
    Publication date: April 10, 2008
    Applicants: Wyeth, Nathan S. Kline Research Institute
    Inventors: Suzana Petanceska, Sam Gandy, Donald Frail